Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.
The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.
Chest pain in patients with aspirin-exacerbated respiratory disease (November 2016)
Aspirin-exacerbated respiratory disease (AERD) describes patients with asthma and chronic rhinosinusitis with nasal polyposis who experience acute nasal symptoms and asthmatic reactions following the ingestion of aspirin and other nonsteroidal antiinflammatory drugs. Retrosternal chest pain may be another less common clinical feature of this syndrome. In a retrospective review of 153 individuals with AERD, 10 patients had been evaluated for chest pain that was variably associated with peripheral blood eosinophilia and vasospasm on angiography . The pain did not respond to angina treatments but did improve with glucocorticoids. Further study of this possible feature of AERD is needed. (See "Aspirin-exacerbated respiratory disease", section on 'Chest pain'.)
Investigational interleukin-5 receptor antibody for asthma (November 2016)
Two trials found that an investigational anti-interleukin (IL)-5 receptor antibody, benralizumab, reduced exacerbations in patients with moderate to severe asthma who had elevated peripheral blood eosinophil counts.
●In the multicenter SIROCCO trial, about 1200 adolescent and adult patients with severe asthma and at least two exacerbations in the prior year despite high-dose inhaled glucocorticoids and a long-acting beta agonist were randomly assigned to subcutaneous benralizumab or placebo for 11 months . Benralizumab reduced exacerbations by approximately 50 percent in patients with a high peripheral blood eosinophil count (≥300/microL).
●In the CALIMA trial, approximately 1300 patients with moderate-to-severe asthma received benralizumab or placebo for 14 months . Among those with high peripheral blood eosinophil counts, the annual exacerbation rate was decreased in the benralizumab groups by 28 to 36 percent, compared with placebo.
In both studies, effects were less consistent for patients with lower eosinophil counts. The subcutaneous drug was well tolerated and might be effective with dosing every eight weeks. Benralizumab is not commercially available. (See "Investigational agents for asthma", section on 'Anti-IL-5 therapy'.)
Safety of inhaled glucocorticoid-LABA combination therapy in asthma (September 2016)
In early studies, a small increase in asthma-related deaths associated with salmeterol led the US Food and Drug Administration to place a boxed warning on the use of long-acting beta agonists (LABAs) in asthma. While concerning, the number of events was small, and it could not be determined if the potential risk of salmeterol could be mitigated by combining LABAs with inhaled glucocorticoids. Three large randomized trials including 30,000 children and adults found no increase in asthma-related adverse events or deaths among patients who used combination inhalers with salmeterol or formoterol plus an inhaled glucocorticoid versus glucocorticoid monotherapy [4-6]. These studies support the safety of these fixed-dose combination inhalers in patients with moderate-to-severe asthma. (See "Beta agonists in asthma: Controversy regarding chronic use", section on 'Potential risk mitigation'.)
Farm animals, asthma, and the innate immune response (September 2016)
Exposure to farm animals, particularly early in life, is negatively associated with the development of allergic disease. A recent study compared 60 children from Amish and Hutterite communities, two genetically similar, reproductively isolated farming populations in the United States . The Amish have traditional, single-family farms with exposure to horses and dairy cows, whereas the Hutterites live and work on large farms that are highly industrialized. Amish children have significantly lower rates of asthma and allergic sensitization than their Hutterite counterparts. Endotoxin levels were significantly higher in the Amish homes, and dust extracts from the Amish homes, but not the Hutterite homes, significantly blocked airway hyperresponsiveness and eosinophilia in a mouse model. In addition, in vitro studies showed an enhanced innate immune response in Amish, but not Hutterite, children. These findings suggest that the closer contact with farm animals in the Amish lifestyle may help prevent the development of asthma by altering the innate immune response. (See "Increasing prevalence of asthma and allergic rhinitis and the role of environmental factors", section on 'Farms, villages, worms, and other parasites'.)
Lack of association between acetaminophen and asthma in children (September 2016)
More frequent use of acetaminophen was associated with increased asthma-related complications in children in observational studies, leading to the recommendation by some for children with asthma to avoid acetaminophen. However, these findings were not replicated in a prospective, randomized trial comparing acetaminophen and ibuprofen use . In this trial, 300 children with mild persistent asthma were randomly assigned to as-needed treatment with acetaminophen or ibuprofen for fever or pain over a 48-week period. All children received standard controller therapy for asthma. There was no significant difference between the two groups in the number of asthma exacerbations requiring treatment with systemic glucocorticoids or in the number of asthma exacerbations. Thus, we do not advise restricting the use of acetaminophen in children with asthma. (See "Virus-induced wheezing and asthma: An overview", section on 'Acetaminophen use for febrile illnesses'.)
Evaluation of recurrent wheezing in children <2 years of age (August 2016)
The American Thoracic Society has developed guidelines for evaluation of children <2 years of age who have recurrent wheezing that is unresponsive to bronchodilators or inhaled or systemic glucocorticoids . Suggested evaluation includes one or more of the following: videofluoroscopic swallowing study (modified barium swallow) for possible swallowing dysfunction; 24-hour esophageal pH monitoring for assessment of gastroesophageal reflux; and/or flexible fiberoptic bronchoscopy bronchoalveolar lavage (BAL) to assess for lower airway bacterial infection. Our approach is consistent with these guidelines. (See "Approach to wheezing in infants and children", section on 'Radiography' and "Approach to wheezing in infants and children", section on 'Endoscopy' and "Approach to wheezing in infants and children", section on 'Evaluation for gastroesophageal reflux'.)
Omalizumab for allergic asthma in children 6 to 11 years of age (July 2016)
Omalizumab, a monoclonal antibody to immunoglobulin E (IgE), is an option for patients with moderate to severe persistent asthma and sensitization to perennial aeroallergens who are inadequately controlled on inhaled glucocorticoids. The US Food and Drug Administration (FDA) has now lowered the approved age range from 12 to 6 years of age, expanding the therapeutic options in step 5 asthma management in children . (See "Asthma in children younger than 12 years: Treatment of persistent asthma with controller medications", section on 'Step-up therapy' and "Asthma in children younger than 12 years: Treatment of persistent asthma with controller medications", section on 'Anti-IgE therapy' and "Anti-IgE therapy", section on 'Omalizumab therapy in asthma'.)
Lack of benefit for long-term oxygen therapy for COPD with mild-to-moderate hypoxemia (November 2016)
While long-term oxygen has demonstrated benefit in severe hypoxemia due to chronic obstructive pulmonary disease (COPD), effectiveness in patients with mild-to-moderate hypoxemia has been unclear. The long-term oxygen treatment trial (LOTT) enrolled over 700 adults with COPD and mild-to-moderate hypoxemia, based on defined parameters of resting and post-walk test oxygen saturation . Participants were randomized to supplemental oxygen (either continuous, with exercise or sleep, depending on hypoxemia pattern) or no supplemental oxygen. There were no differences in time to death or first hospitalization, COPD exacerbations, quality of life, or exercise capacity at one to six years. While supplemental oxygen does not appear to benefit most patients with mild-to-moderate hypoxemia, the possibility of benefit for individual patients is not excluded. (See "Management of stable chronic obstructive pulmonary disease", section on 'Oxygen'.)
Controlled effectiveness trial of fluticasone furoate-vilanterol in COPD (November 2016)
One concern about randomized trials of chronic obstructive pulmonary disease (COPD) therapies is that their strict selection criteria exclude higher-risk patients and potentially miss adverse effects that could occur in routine clinical practice. A multicenter controlled effectiveness trial recruited almost 3000 patients with COPD who had had one or more exacerbations in the prior three years and assigned them to fluticasone furoate-vilanterol (100 mcg-25 mcg) once daily or usual care for one year . The fluticasone furoate-vilanterol group experienced approximately 8 percent fewer exacerbations. The trial did not demonstrate a significant difference in the incidence of pneumonia between the groups. (See "Management of stable chronic obstructive pulmonary disease", section on 'Efficacy'.)
High-flow oxygen for the prevention of postextubation respiratory failure (October 2016)
Results from trials that compare high-flow oxygen delivered via nasal cannula (HFNC) and noninvasive ventilation (NIV) for the prevention of postextubation respiratory failure have been conflicting. In a recent multicenter trial of patients at high risk of reintubation following extubation, rates of reintubation, the primary outcome, were similar for NIV and HFNC, and there was no difference in rates of mortality, sepsis, or multiorgan failure . For patients considered at high risk of reintubation, this study supports the use of a trial of HFNC as an alternative to NIV for those at high risk of reintubation. However, given conflicting earlier findings, additional trials are needed to determine strict selection criteria before routinely recommending HFNC for the prevention of postextubation respiratory failure. (See "Extubation management", section on 'High flow oxygen versus noninvasive ventilation'.)
Corticosteroids not beneficial in severe sepsis without shock (October 2016)
The administration of corticosteroids to patients with sepsis is generally reserved for those with septic shock. A recent randomized trial of nearly 400 adults examined the efficacy of corticosteroids in patients with severe sepsis who did not have shock . Compared with placebo, an infusion of hydrocortisone (200 mg daily for five days followed by tapering until day 11) had no effect on mortality or progression to shock. This trial supports our current recommendation that corticosteroids not be routinely administered to septic patients without shock. (See "Glucocorticoid therapy in septic shock", section on 'HYPRESS'.)
Oxygenation goals in critically ill patients (October 2016)
The optimal level of oxygenation in mechanically ventilated patients is unknown. A recent randomized trial reported that, compared with a conventional approach to oxygenation (partial arterial pressure of oxygen [PaO2] up to 150 mmHg or peripheral arterial oxygen saturation [SpO2] 97 to 100 percent), a conservative approach (PaO2 70 to 100 mmHg or SpO2 94 to 98 percent) resulted in lower mortality and fewer episodes of shock, liver failure, and bacteremia . However, these preliminary results should be confirmed by a larger multicenter trial before a conservative approach to oxygenation should be routinely adopted for mechanically ventilated patients. (See "Overview of mechanical ventilation", section on 'Fraction of inspired oxygen'.)
Early mobilization in critically ill patients (July 2016, Modified October 2016)
Two recent trials on the role of physical therapy for early mobilization of critically ill patients report conflicting outcomes:
●One trial of mechanically ventilated surgical intensive care unit (ICU) patients reported that compared with usual care, implementation of a rigid goal-directed early mobilization strategy resulted in improved mobilization scores, decreased ICU length of stay, improved functional mobility at hospital discharge, and possibly improved mortality .
●A single-center trial of 300 critically ill ventilated patients reported no benefit for an intensive daily physical rehabilitation regimen initiated in the ICU and continued until hospital discharge, when compared with usual care (ie, intervention as needed when requested by the health care team) .
Findings from the trial reporting benefit may be more reliable, because the communication loop that was in place ensured that patients actually received the physical therapy intervention. Nonetheless, these findings need to be replicated before early mobilization can be routinely recommended. (See "Post-intensive care syndrome (PICS)", section on 'Prevention'.)
IDSA/ATS guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia (August 2016)
The Infectious Diseases Society of America and the American Thoracic Society have released updated guidelines for the management of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) . Empiric therapy for HAP (algorithm 1) and VAP (algorithm 2) should include agents with activity against Staphylococcus aureus, Pseudomonas aeruginosa, and other gram-negative bacilli. Choice of a specific regimen for empiric therapy should be based upon knowledge of the prevailing pathogens (and susceptibility patterns) within the healthcare setting as well as risk factors for multidrug resistance in the individual patient. The guidelines emphasize that a seven-day course of antimicrobial therapy is appropriate for most patients rather than a longer duration. (See "Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Treatment'.)
Palliative care consultation for families of patients in the intensive care unit (August 2016)
Post-intensive care syndrome-family (PICS-F) is a term given to family members who have been affected physically and psychologically during the intensive care unit (ICU) stay of critically ill patients. Therapeutic measures for PICS-F are poorly studied. One multicenter randomized trial examined the impact of a palliative care-led consultation for surrogate decision-makers of critically ill patients in the ICU who were unlikely to wean from mechanical ventilation . Compared with routine family meetings conducted by the ICU team, palliative care-led consultation did not reduce symptoms of anxiety or depression of family members and may have increased symptoms of posttraumatic stress disorder. However, limitations of this study include possible inadequate "dosing" of the intervention (on average, 1.4 encounters per family and physician presence at only 9 percent of meetings), leaving the possibility that more aggressive and supportive interventions may have different outcomes. (See "Post-intensive care syndrome (PICS)", section on 'Post-intensive care syndrome-family'.)
Aspirin does not prevent acute respiratory distress syndrome in adults (July 2016)
Preclinical and clinical observational studies have suggested a potential role for aspirin in the prevention of acute respiratory distress syndrome (ARDS). The ability of aspirin to prevent ARDS was tested in a randomized trial of 390 patients who were assessed upon presentation to an emergency department to be at risk of developing ARDS . Aspirin, administered at 325 mg orally followed by 81 mg daily for seven days, had no effect on the incidence of ARDS at one week (approximately 10 percent in each group). However, the lower than expected rate of ARDS in this study may have limited the potential to detect a study drug effect. (See "Acute respiratory distress syndrome: Investigational or ineffective pharmacotherapy in adults", section on 'Aspirin'.)
INTERSTITIAL LUNG DISEASE
Mycophenolate mofetil for scleroderma lung disease (October 2016)
Cyclophosphamide has been the suggested treatment for moderate-to-severe interstitial lung disease complicating systemic sclerosis (SSc-ILD) but has well-known toxicity. A recent randomized trial compared mycophenolate mofetil (MMF) with oral cyclophosphamide in 142 patients with SSc-ILD, exertional dyspnea, and features of progressive disease . Pulmonary function and dyspnea improved in both groups, without a significant difference between groups. MMF was better tolerated than cyclophosphamide based on a longer time to patient withdrawal and lower incidence of leukopenia and thrombocytopenia. We now suggest initiating treatment for symptomatic progressive SSc-ILD with mycophenolate, rather than cyclophosphamide, due to comparable efficacy, better safety profile, and the option for longer-term therapy. (See "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Choice of an agent'.)
Revised criteria for acute exacerbations of idiopathic pulmonary fibrosis (August 2016)
An international working group has published a comprehensive review of acute exacerbations of idiopathic pulmonary fibrosis (IPF) that includes a revised definition and diagnostic criteria. The report defines an acute exacerbation of IPF as, "an acute, clinically significant respiratory deterioration characterized by evidence of new widespread alveolar abnormality" . The following diagnostic criteria are suggested: a previous or concurrent diagnosis of IPF; acute worsening or development of dyspnea typically within one month of presentation; high-resolution computed tomography with new bilateral ground-glass abnormality and/or consolidation superimposed on usual interstitial pneumonia (eg, bibasilar reticular opacities associated with honeycomb changes and traction bronchiectasis); deterioration not fully explained by cardiac failure or fluid overload. Previous criteria required exclusion of other causes of acute deterioration, such as infection or pulmonary embolism. (See "Treatment of idiopathic pulmonary fibrosis".)
PULMONARY VASCULAR DISEASE
Syncope and pulmonary embolus (October 2016)
While pulmonary embolus (PE) has generally been considered to be a relatively rare cause of syncope, a recent study reported a 17 percent prevalence of PE among patients admitted to hospital with syncope, and a 25 percent prevalence among those without an alternative etiology for syncope . Two-thirds of patients with syncope secondary to PE had thrombus located in the mainstem or lobar arteries, suggesting that syncope may indicate a high burden of thrombus. The study underscores the importance of syncope as a presenting manifestation of clinically significant PE. (See "Clinical presentation, evaluation, and diagnosis of the adult with suspected acute pulmonary embolism", section on 'History and examination'.)
Inadequate sleep and adverse cardiometabolic outcomes (December 2016)
The adverse health outcomes of inadequate sleep duration (<7 hours per night) and quality are increasingly recognized. A new scientific statement from the American Heart Association reviews data linking sleep restriction with adverse cardiometabolic outcomes and recommends that healthy sleep behavior be addressed in public health campaigns to promote ideal cardiac health, alongside blood pressure, cholesterol, diet, blood glucose, physical activity, weight, and smoking cessation . (See "Insufficient sleep: Definition, epidemiology, and adverse outcomes", section on 'Cardiovascular morbidity'.)
Flumazenil in patients with refractory hypersomnolence (December 2016)
Preliminary data suggest that compounded preparations of flumazenil, a gamma-aminobutyric acid type A receptor antagonist, may benefit some patients with hypersomnolence of central origin. In a case series of 153 patients with refractory hypersomnolence due to idiopathic hypersomnia, obstructive sleep apnea, or other disorders, compounded sublingual or transdermal flumazenil was well tolerated and associated with sustained improvement in subjective sleepiness in 39 percent of patients . These results suggest that controlled studies of flumazenil in this patient population are warranted. (See "Idiopathic hypersomnia", section on 'Pharmacotherapy'.)
CPAP in obstructive sleep apnea does not reduce cardiovascular events (August 2016)
Whether continuous positive airway pressure (CPAP) therapy can reduce the increased risk of cardiovascular morbidity and mortality associated with obstructive sleep apnea (OSA) is unknown. The largest trial to address this issue randomized 2717 patients with moderate to severe OSA and established cardiovascular disease to CPAP therapy plus usual care or usual care alone (eg, education, risk factor modification) and followed patients for 3.7 years . Despite adequate control of OSA, there was no difference in cardiovascular events (eg, cardiovascular deaths, myocardial infarction, or stroke). However, the exclusion of patients who are among the most likely to benefit from CPAP (eg, patients with “sleepy” OSA) and a low adherence rate to therapy (mean was 3.3 hours per night) may have limited the potential benefit from this therapy. While the cardiovascular benefits are unproven, CPAP should be administered for the associated noncardiovascular benefits (eg, improvement in symptoms and quality of life) and should remain the mainstay of therapy for patients with moderate to severe OSA. (See "Obstructive sleep apnea and cardiovascular disease", section on 'Cardiovascular events'.)
Chronic sleep-wake disturbances after traumatic brain injury (July 2016)
Sleep-wake disturbances are very common in the weeks to months following traumatic brain injury (TBI), and a new study suggests that many of these symptoms persist long term. In a prospective case-control study in which 31 patients with TBI of any severity were evaluated at 18 months after injury, 67 percent of patients had evidence of excessive daytime sleepiness on objective testing, compared with only 19 percent of healthy controls . Patients also had persistent pleiosomnia (increased need for sleep), requiring an average of one more hour of sleep per 24 hours than controls. As in earlier studies, patients tended to underestimate their symptoms, emphasizing the importance of both subjective and objective sleep testing in patients with sleep-wake complaints after TBI. (See "Sleep-wake disorders in patients with traumatic brain injury", section on 'Natural history'.)
Prevalence of central sleep apnea in the community (July 2016)
Central sleep apnea (CSA) occurs with increased frequency in patients with heart failure and other comorbid cardiovascular diseases, but the prevalence in the general population has not been well established. In a population-based study of over 5000 community-dwelling adults age 40 years and older who underwent polysomnography, the prevalence of CSA was 0.9 percent . By comparison, obstructive sleep apnea was present in 48 percent of patients. Risks factors for CSA included age older than 65 years, male gender, and self-reported heart failure. Cheyne-Stokes breathing was present in approximately half of patients with CSA. (See "Central sleep apnea: Risk factors, clinical presentation, and diagnosis", section on 'Epidemiology'.)
OTHER PULMONARY MEDICINE
Diaphragmatic pacing harmful in patients with amyotrophic lateral sclerosis (January 2017)
Pacing the diaphragm in patients with amyotrophic lateral sclerosis (ALS) is controversial. A recent randomized trial of patients with early respiratory impairment from ALS reported that, compared with sham pacing, diaphragmatic pacing resulted in increased mortality and did not delay time to noninvasive ventilation . We continue to prefer to avoid diaphragmatic pacing in this population until future trials demonstrate a clear benefit. (See "Pacing the diaphragm: Patient selection, evaluation, implantation, and complications", section on 'Amyotrophic lateral sclerosis'.)
Guidelines on diagnosis of tuberculosis (January 2017)
Guidelines from the American Thoracic Society, Infectious Diseases Society of America, and the Centers for Disease Control and Prevention on the diagnosis of tuberculosis in adults and children were published in December 2016 . They state that an interferon-gamma release assay (IGRA) is generally preferred for diagnosis of latent tuberculosis infection (LTBI) in individuals five years or older who have low-to-intermediate risk of progression to active disease (table 1), although the tuberculin skin test (TST) is an acceptable alternative if IGRA is not available or too costly. For those who have high risk of progression to active disease, either IGRA or TST is acceptable, but many guideline panel members noted using the alternative test if the initial one was negative and considering a positive result from either test to indicate LTBI. The evaluation of suspected tuberculosis disease should include three sputum specimens for acid-fast bacilli (AFB) smear and culture and one or more specimens for nucleic acid amplification (NAA) testing. (See "Diagnosis of latent tuberculosis infection (tuberculosis screening) in HIV-uninfected adults" and "Diagnosis of pulmonary tuberculosis in HIV-uninfected patients" and "Latent tuberculosis infection in children" and "Tuberculosis disease in children".)
FDA warning removed from varenicline for smoking cessation (December 2016)
In 2009, the US Food and Drug Administration (FDA) required varenicline packaging to include a boxed warning about potential neuropsychiatric side effects, but this warning has been removed in 2016 , based on results of a randomized trial that found no difference in adverse neuropsychiatric events comparing varenicline with nicotine patch or placebo in patients with or without a coexisting psychiatric disorder . As with any medication, we advise that patients should be told to contact their clinician if they or their family notice any unusual behavior or mood symptoms as well as any new or worsening symptoms of cardiovascular disease. (See "Pharmacotherapy for smoking cessation in adults", section on 'Safety'.)
Ibrutinib and Pneumocystis pneumonia (December 2016)
The Bruton tyrosine kinase inhibitor ibrutinib has not clearly been associated with an increased risk of opportunistic infections, but cases have been reported. In a series of 96 patients receiving ibrutinib as the sole agent for chronic lymphocytic leukemia (CLL), five were reported to have Pneumocystis pneumonia . All of the infections were grade ≤2 and resolved with oral trimethoprim-sulfamethoxazole. A limitation is that the diagnoses were made by polymerase chain reaction (PCR) of bronchoalveolar lavage fluid, which could represent a false positive in the setting of colonization with Pneumocystis. Nevertheless, clinicians should have a high index of suspicion for Pneumocystis pneumonia in patients receiving ibrutinib, and the diagnosis should be sought in those with compatible signs and symptoms. (See "Risk of infections in patients with chronic lymphocytic leukemia", section on 'Ibrutinib' and "Prevention of infections in patients with chronic lymphocytic leukemia", section on 'Ibrutinib and idelalisib'.)
E-cigarette use and respiratory symptoms in adolescents (November 2016)
Use of e-cigarettes has been rising among adolescents in the United States, and the long-term health consequences of e-cigarette use are unknown. A survey of 11th and 12th grade students in California found an association between self-reported chronic bronchitic symptoms (chronic cough, phlegm, bronchitis in the past year) and current or past e-cigarette use that remained after adjustment for confounders such as cigarette smoking or secondhand smoke exposure; risk of respiratory symptoms increased with frequency of current use of e-cigarettes . (See "E-cigarettes", section on 'Adverse health effects'.)
New guideline recommendations on treatment of drug-susceptible tuberculosis in HIV-infected patients (September 2016)
For patients with tuberculosis (TB) and newly diagnosed HIV infection, a number of trials have established the benefits of initiating antiretroviral therapy (ART) soon after initiating TB therapy. New guidelines on the treatment of drug-susceptible tuberculosis (TB), developed jointly by the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America, also recommend initiating ART during TB treatment (within the first two weeks if the CD4 cell count <50 cells/microL and within 8 to 12 weeks if the CD4 cell count >50 cells/microL), rather than waiting until after TB therapy is completed . However, HIV-infected patients with TB involvement of the central nervous system (CNS) are an exception; for these patients, the guidelines recommend against initiating ART in the first eight weeks of antituberculous therapy (even for patients with CD4 cell counts <50 cells/microL), since development of immune reconstitution inflammatory syndrome in patients with CNS TB may cause severe or fatal neurological complications. (See "Treatment of pulmonary tuberculosis in HIV-infected adults", section on 'Timing of ART in the treatment-naive patient' and "Central nervous system tuberculosis".)
IDSA guidelines on the management of aspergillosis (July 2016)
The Infectious Diseases Society of America released updated guidelines for the treatment of aspergillosis [36,37]. Voriconazole remains the mainstay of therapy for invasive aspergillosis. In contrast with the previous version of the guidelines, the updated version suggests consideration of combination therapy with voriconazole plus an echinocandin for initial therapy of severe invasive aspergillosis, particularly in patients with hematologic malignancy and/or in those with profound and persistent neutropenia. We generally agree with these guidelines and suggest combination therapy with voriconazole plus an echinocandin for patients with severe, microbiologically documented invasive aspergillosis, but we also consider combination therapy for all patients with an immunocompromising condition that led to disease. (See "Treatment and prevention of invasive aspergillosis", section on 'Guidelines'.)
- Shah NH, Schneider TR, DeFaria Yeh D, et al. Eosinophilia-Associated Coronary Artery Vasospasm in Patients with Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract 2016; 4:1215.
- Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388:2115.
- FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388:2128.
- Stempel DA, Raphiou IH, Kral KM, et al. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. N Engl J Med 2016; 374:1822.
- Stempel DA, Szefler SJ, Pedersen S, et al. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. N Engl J Med 2016; 375:840.
- Peters SP, Bleecker ER, Canonica GW, et al. Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone. N Engl J Med 2016; 375:850.
- Stein MM, Hrusch CL, Gozdz J, et al. Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children. N Engl J Med 2016; 375:411.
- Sheehan WJ, Mauger DT, Paul IM, et al. Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma. N Engl J Med 2016; 375:619.
- Official American Thoracic Society Clinical Practice Guidelines: Diagnostic Evaluation of Infants with Recurrent or Persistent Wheezing. http://www.thoracic.org/about/newsroom/press-releases/journal/wheezing-in-infants.pdf.
- Omalizumab. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103976s5225lbl.pdf (Accessed on July 13, 2016).
- Long-Term Oxygen Treatment Trial Research Group. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med 2016; 375:1617.
- Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. N Engl J Med 2016; 375:1253.
- Hernández G, Vaquero C, González P, et al. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial. JAMA 2016; 315:1354.
- Keh D, Trips E, Marx G, et al. Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial. JAMA 2016; 316:1775.
- Girardis M, Busani S, Damiani E, et al. Effect of Conservative vs Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: The Oxygen-ICU Randomized Clinical Trial. JAMA 2016; 316:1583.
- Schaller SJ, Anstey M, Blobner M, et al. Early, goal-directed mobilisation in the surgical intensive care unit: a randomised controlled trial. Lancet 2016; 388:1377.
- Morris PE, Berry MJ, Files DC, et al. Standardized Rehabilitation and Hospital Length of Stay Among Patients With Acute Respiratory Failure: A Randomized Clinical Trial. JAMA 2016; 315:2694.
- Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61.
- Carson SS, Cox CE, Wallenstein S, et al. Effect of Palliative Care-Led Meetings for Families of Patients With Chronic Critical Illness: A Randomized Clinical Trial. JAMA 2016; 316:51.
- Kor DJ, Carter RE, Park PK, et al. Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial. JAMA 2016; 315:2406.
- Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4:708.
- Collard HR, Ryerson CJ, Corte TJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med 2016; 194:265.
- Prandoni P, Lensing AW, Prins MH, et al. Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope. N Engl J Med 2016; 375:1524.
- St-Onge MP, Grandner MA, Brown D, et al. Sleep Duration and Quality: Impact on Lifestyle Behaviors and Cardiometabolic Health: A Scientific Statement From the American Heart Association. Circulation 2016; 134:e367.
- Trotti LM, Saini P, Koola C, et al. Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients. J Clin Sleep Med 2016; 12:1389.
- McEvoy RD, Antic NA, Heeley E, et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. N Engl J Med 2016; 375:919.
- Imbach LL, Büchele F, Valko PO, et al. Sleep-wake disorders persist 18 months after traumatic brain injury but remain underrecognized. Neurology 2016; 86:1945.
- Donovan LM, Kapur VK. Prevalence and Characteristics of Central Compared to Obstructive Sleep Apnea: Analyses from the Sleep Heart Health Study Cohort. Sleep 2016; 39:1353.
- Gonzalez-Bermejo J, Morélot-Panzini C, Tanguy ML, et al. Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. Lancet Neurol 2016; 15:1217.
- Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2016.
- Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016; 387:2507.
- Ahn IE, Jerussi T, Farooqui M, et al. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood 2016; 128:1940.
- McConnell R, Barrington-Trimis JL, Wang K, et al. Electronic-cigarette Use and Respiratory Symptoms in Adolescents. Am J Respir Crit Care Med 2016.
- Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.
- Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327.
- Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183:96.